Skip to menu Skip to content Skip to footer
Dr Sandra Brosda
Dr

Sandra Brosda

Email: 

Overview

Background

Dr Sandra Brosda is a Research Fellow within the Surgical Oncology group led by Professor Andrew Barbour.

Dr Brosda was awarded a PhD in bioinformatics and cancer genetics from the University of Queensland in November 2020. Her research focused on biomarker discovery and intra-tumour heterogeneity and tumour evolution in oesophageal adenocarcinoma (OAC). In 2021, Dr Brosda was awarded a Cure Cancer Australia PdCCRS grant and an MSH project grant to further investigate tumour evolution to improve precision medicine in OAC.

She has been involved in research projects covering genetics, epigenetics, spatial transcriptomics, radiomics, ctDNA and quality of life assessments in the context of cancer. Overall, her research applies bioinformatics tools and approaches to cancer genomics to improve precision medicine and health outcomes for patients with melanoma, oesophago-gastric cancer and pancreatic cancer.

Availability

Dr Sandra Brosda is:
Available for supervision

Qualifications

  • Bachelor of Bioinformatics, University of Bielefeld
  • Masters (Coursework) of Bioinformatics, University of Bielefeld
  • Doctor of Philosophy, The University of Queensland

Research interests

  • Bioinformatics

  • Intra-tumour heterogeneity

  • Tumour evolution

  • Cancer genetics

Works

Search Professor Sandra Brosda’s works on UQ eSpace

24 works between 2016 and 2024

1 - 20 of 24 works

Featured

2024

Journal Article

Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy

Brosda, Sandra, Aoude, Lauren G., Bonazzi, Vanessa F., Patel, Kalpana, Lonie, James M., Belle, Clemence J., Newell, Felicity, Koufariotis, Lambros T., Addala, Venkateswar, Naeini, Marjan M., Simes, John, Walpole, Euan T., Mai, Gang T., Watson, David I., Karapetis, Chris S., Gebski, Val, Barnes, Elizabeth H., Oostendorp, Martijn, Wilson, Kate, Ackland, Stephen P., Shannon, Jenny, Marx, Gavin, Burge, Matthew, Finch, Robert, Thomas, Janine, Varma, Suresh, Nott, Louise, Pearson, John V., Krause, Lutz ... AGITG DOCTOR Investigators (2024). Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy. Genome Medicine, 16 (1) 90, 90. doi: 10.1186/s13073-024-01362-z

Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy

2024

Journal Article

Intra‐tumoral and peripheral blood <scp>TIGIT</scp> and <scp>PD</scp>‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma

Gunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Fennell, Éanna, Hennessy, Aoife, Leahy, Ciara I., Murray, Paul G., Bednarska, Karolina, Brosda, Sandra, Trotman, Judith, Berkahn, Leanne, Zaharia, Andreea, Birch, Simone, Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Snell, Cameron, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Shanavas, Mohamed, Blyth, Emily, Steidl, Christian, Savage, Kerry, Farinha, Pedro ... Gandhi, Maher K. (2024). Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma. American Journal of Hematology. doi: 10.1002/ajh.27459

Intra‐tumoral and peripheral blood <scp>TIGIT</scp> and <scp>PD</scp>‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma

2023

Journal Article

Tumour microenvironment influences response to treatment in oesophageal adenocarcinoma

Belle, Clemence J., Lonie, James M., Brosda, Sandra and Barbour, Andrew P. (2023). Tumour microenvironment influences response to treatment in oesophageal adenocarcinoma. Frontiers in Immunology, 14 1330635, 1-8. doi: 10.3389/fimmu.2023.1330635

Tumour microenvironment influences response to treatment in oesophageal adenocarcinoma

2023

Journal Article

The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank

Lonie, James M., Brosda, Sandra, Bonazzi, Vanessa F., Aoude, Lauren G., Patel, Kalpana, Brown, Ian, Sharma, Sowmya, Lampe, Guy, Addala, Venkateswar, Koufariotis, Lambros T., Wood, Scott, Waddell, Nicola, Dolcetti, Riccardo and Barbour, Andrew P. (2023). The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank. Frontiers in Immunology, 14 1220129, 1-15. doi: 10.3389/fimmu.2023.1220129

The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank

2023

Journal Article

ctDNA: a promising biomarker for predicting recurrence in BRAF-negative melanoma patients

Aoude, Lauren G., Brosda, Sandra, Ng, Jessica, Lonie, James M., Belle, Clemence J., Patel, Kalpana, Koufariotis, Lambros T., Wood, Scott, Atkinson, Victoria, Smithers, B. Mark, Pearson, John V., Waddell, Nicola, Barbour, Andrew P. and Bonazzi, Vanessa F. (2023). ctDNA: a promising biomarker for predicting recurrence in BRAF-negative melanoma patients. Journal of Molecular Diagnostics, 25 (10), 771-781. doi: 10.1016/j.jmoldx.2023.06.014

ctDNA: a promising biomarker for predicting recurrence in BRAF-negative melanoma patients

2023

Journal Article

C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients

Bonazzi, Vanessa F., Aoude, Lauren G., Brosda, Sandra, Bradford, Julia J., Lonie, James M., Loffler, Kelly A., Gartside, Michael G., Patel, Kalpana, Mukhopadhyay, Pamela, Keane, Colm, Gebski, Val, Kench, James G., Goldstein, David, Waddell, Nicola, Barbour, Andrew P. and the Australasian Gastro‐Intestinal Trials Group (AGITG) GAP investigators (2023). C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients. Asia-Pacific Journal of Clinical Oncology. doi: 10.1111/ajco.13993

C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients

2023

Journal Article

Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy

M. Naeini, Marjan, Newell, Felicity, Aoude, Lauren G., Bonazzi, Vanessa F., Patel, Kalpana, Lampe, Guy, Koufariotis, Lambros T., Lakis, Vanessa, Addala, Venkateswar, Kondrashova, Olga, Johnston, Rebecca L., Sharma, Sowmya, Brosda, Sandra, Holmes, Oliver, Leonard, Conrad, Wood, Scott, Xu, Qinying, Thomas, Janine, Walpole, Euan, Tao Mai, G., Ackland, Stephen P., Martin, Jarad, Burge, Matthew, Finch, Robert, Karapetis, Christos S., Shannon, Jenny, Nott, Louise, Bohmer, Robert, Wilson, Kate ... Waddell, Nicola (2023). Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy. Nature Communications, 14 (1) 3155, 3155. doi: 10.1038/s41467-023-38891-x

Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy

2022

Conference Publication

Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma

Gunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Bednarska, Karolina, Brosda, Sandra, Zaharia, Andreea, Tsang, Hennes, de Long, Lilia M., Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Gould, Clare, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Birch, Simone, Shanavas, Mohamed, Snell, Cameron and Gandhi, Maher K. (2022). Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma. Third AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application, 23-25 June 2022, Boston, MA USA. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/2643-3249.lymphoma22-a17

Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma

2022

Conference Publication

Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma

Aoude, L.G., Bonazzi, V.F., Brosda, S., Wong, B., Moradi, H., Lonie, J., Bradford, J., Bloxham, C., Atkinson, V.G., Law, P., Lampe, G., Smithers, M., Waddell, N., Vegh, V., Miles, K. and Barbour, A.P. (2022). Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma. ESMO Congress 2022, Singapore, 9 - 13 September 2022. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2022.07.1357

Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma

2022

Journal Article

Elevation of fatty acid desaturase 2 in esophageal adenocarcinoma increases polyunsaturated lipids and may exacerbate bile acid‐induced DNA damage

Molendijk, Jeffrey, Kolka, Cathryn M., Cairns, Henry, Brosda, Sandra, Mohamed, Ahmed, Shah, Alok K., Brown, Ian, Hodson, Mark P., Hennessy, Thomas, Liu, Guanghao, Stoll, Thomas, Richards, Renee S., Gartside, Michael, Patel, Kalpana, Clemons, Nicholas J., Phillips, Wayne A., Barbour, Andrew, Westerhuis, Johan A. and Hill, Michelle M. (2022). Elevation of fatty acid desaturase 2 in esophageal adenocarcinoma increases polyunsaturated lipids and may exacerbate bile acid‐induced DNA damage. Clinical and Translational Medicine, 12 (5) e810, 1-19. doi: 10.1002/ctm2.810

Elevation of fatty acid desaturase 2 in esophageal adenocarcinoma increases polyunsaturated lipids and may exacerbate bile acid‐induced DNA damage

2022

Journal Article

ctDNA as a biomarker of progression in oesophageal adenocarcinoma

Bonazzi, V. F., Aoude, L. G., Brosda, S., Lonie, J. M., Patel, K., Bradford, J. J., Koufariotis, L. T., Wood, S., Smithers, B. Mark, Waddell, N. and Barbour, A. P. (2022). ctDNA as a biomarker of progression in oesophageal adenocarcinoma. ESMO Open, 7 (3) 100452, 100452. doi: 10.1016/j.esmoop.2022.100452

ctDNA as a biomarker of progression in oesophageal adenocarcinoma

2022

Journal Article

C5b-9 membrane attack complex formation and extracellular vesicle shedding in Barrett’s esophagus and esophageal adenocarcinoma

Kolka, Cathryn M., Webster, Julie, Lepletier, Ailin, Winterford, Clay, Brown, Ian, Richards, Renee S., Zelek, Wioleta M., Cao, Yilang, Khamis, Ramlah, Shanmugasundaram, Karthik B., Wuethrich, Alain, Trau, Matt, Brosda, Sandra, Barbour, Andrew, Shah, Alok K., Eslick, Guy D., Clemons, Nicholas J., Morgan, B. Paul and Hill, Michelle M. (2022). C5b-9 membrane attack complex formation and extracellular vesicle shedding in Barrett’s esophagus and esophageal adenocarcinoma. Frontiers in Immunology, 13 842023. doi: 10.3389/fimmu.2022.842023

C5b-9 membrane attack complex formation and extracellular vesicle shedding in Barrett’s esophagus and esophageal adenocarcinoma

2021

Journal Article

Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patients

Aoude, Lauren G., Wong, Bernadette, Bonazzi, Vanessa F, Brosda, Sandra, Walters, Shaun B., Koufariotis, Lambros T., Naeini, Marjan M., Pearson, John V, Oey, Harald, Patel, Kalpana, Bradford, Julia J., Bloxham, Conor J, Atkinson, Victoria, Law, Phillip, Strutton, Geoffrey, Bayley, Gerard, Yang, Samuel, Smithers, B. Mark, Waddell, Nicola, Miles, Kenneth and Barbour, Andrew P. (2021). Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patients. Molecular Cancer Research, 19 (6) molcanres.1038.2020, 950-956. doi: 10.1158/1541-7786.mcr-20-1038

Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patients

2021

Journal Article

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

Gandhi, Maher K., Hoang, Thanh, Law, Soi C., Brosda, Sandra, O'Rourke, Kacey, Tobin, Joshua W. D., Vari, Frank, Murigneux, Valentine, Fink, J. Lynn, Gunawardana, Jay, Gould, Clare M., Oey, Harald, Bednarska, Karolina, Delecluse, Susanne, Trappe, Ralf Ulrich, de Long, Lilia Merida, Sabdia, Muhammed Bilal, Bhagat, Govind, Hapgood, Greg, Blyth, Emily, Clancy, Leighton E., Wight, Joel, Hawkes, Eliza A., Rimsza, Lisa M., Maguire, Alanna, Bojarczuk, Kamil, Chapuy, Bjoern and Keane, Colm (2021). EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood, 137 (11), 1468-1477. doi: 10.1182/blood.2020008520

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

2021

Journal Article

Complications and survival after hybrid and fully minimally invasive oesophagectomy

Veenstra, M. M. K., Smithers, B. M., Visser, E., Edholm, D., Brosda, S., Thomas, J. M., Gotley, D. C., Thomson, I. G., Wijnhoven, B. P. L. and Barbour, A. P. (2021). Complications and survival after hybrid and fully minimally invasive oesophagectomy. BJS Open, 5 (1) zraa033, 1-7. doi: 10.1093/bjsopen/zraa033

Complications and survival after hybrid and fully minimally invasive oesophagectomy

2020

Other Outputs

Spatial and temporal tumour evolution and genetic biomarker discovery for personalised treatment in oesophageal adenocarcinoma

Brosda, Sandra (2020). Spatial and temporal tumour evolution and genetic biomarker discovery for personalised treatment in oesophageal adenocarcinoma. PhD Thesis, Medicine Faculty, The University of Queensland. doi: 10.14264/89e3f4f

Spatial and temporal tumour evolution and genetic biomarker discovery for personalised treatment in oesophageal adenocarcinoma

2020

Journal Article

Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients

Aoude, Lauren G., Bonazzi, Vanessa F., Brosda, Sandra, Patel, Kalpana, Koufariotis, Lambros T., Oey, Harald, Nones, Katia, Wood, Scott, Pearson, John V., Lonie, James M., Arneil, Melissa, Atkinson, Victoria, Smithers, B. Mark, Waddell, Nicola and Barbour, Andrew P. (2020). Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific Reports, 10 (1) 17687, 17687. doi: 10.1038/s41598-020-74956-3

Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients

2020

Journal Article

Impact of fruit orientation and pelleting material on water uptake and germination performance in artificial substrate for sugar beet

Blunk, Sebastian, Hoffer, Jeroen, Brosda, Sandra, de Heer, Martine I., Sturrock, Craig J. and Mooney, Sacha J. (2020). Impact of fruit orientation and pelleting material on water uptake and germination performance in artificial substrate for sugar beet. PLoS ONE, 15 (5) e0232875, e0232875. doi: 10.1371/journal.pone.0232875

Impact of fruit orientation and pelleting material on water uptake and germination performance in artificial substrate for sugar beet

2019

Journal Article

Baseline neutrophil–lymphocyte ratio holds no prognostic value for esophageal and junctional adenocarcinoma in patients treated with neoadjuvant chemotherapy

van Hootegem, S. J. M., Smithers, B. M., Gotley, D. C., Brosda, S., Thomson, I. G., Thomas, J. M., Gartside, M. and Barbour, A. P. (2019). Baseline neutrophil–lymphocyte ratio holds no prognostic value for esophageal and junctional adenocarcinoma in patients treated with neoadjuvant chemotherapy. Diseases of the Esophagus, 33 (6). doi: 10.1093/dote/doz082

Baseline neutrophil–lymphocyte ratio holds no prognostic value for esophageal and junctional adenocarcinoma in patients treated with neoadjuvant chemotherapy

2019

Journal Article

The impact of signet ring cell differentiation on outcome in patients with esophageal and gastroesophageal junction adenocarcinoma

van Hootegem, Sander J. M., Smithers, B. Mark, Gotley, David C., Brosda, Sandra, Thomson, Iain G., Thomas, Janine M., Gartside, Michael, van Lanschot, Jan J. B., Lagarde, Sjoerd M., Wijnhoven, Bas P. L. and Barbour, Andrew P. (2019). The impact of signet ring cell differentiation on outcome in patients with esophageal and gastroesophageal junction adenocarcinoma. Annals of Surgical Oncology, 26 (8), 2375-2384. doi: 10.1245/s10434-019-07322-x

The impact of signet ring cell differentiation on outcome in patients with esophageal and gastroesophageal junction adenocarcinoma

Funding

Current funding

  • 2022 - 2024
    Investigating tumour evolution to improve precision medicine in patients with oesophageal adenocarcinoma (MSH RSS Project Grant led by Metro South Health)
    Metro South Hospital and Health Service
    Open grant

Past funding

  • 2022 - 2023
    Investigating the spatial and temporal tumour evolution to improve precision medicine in patients with oesophageal adenocarcinoma
    Cure Cancer Australia Foundation
    Open grant

Supervision

Availability

Dr Sandra Brosda is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

  • Doctor Philosophy

    Deep spatial phenotyping analysis to characterize cancer evolution

    Principal Advisor

    Other advisors: Professor Andrew Barbour

  • Doctor Philosophy

    Haressing tumour immune responses in oesophageal cancer: towards better personalised therapeutic strategies

    Associate Advisor

    Other advisors: Professor Andrew Barbour

Media

Enquiries

For media enquiries about Dr Sandra Brosda's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au